At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)
In Brief
A Phase 3 clinical trial evaluating tamoxifen, anastrozole, and 2 other interventions for Breast Cancer. Completed, enrolled 1,803 participants across 72 sites in 2 countries.
Detailed Summary
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal patients with non-metastatic breast cancer treated with tamoxifen or anastrozole. To assess whether zoledronate added to standard adjuvant therapy can decrease or even prevent bone loss in patients treated with hormonal blockade combined with an antiestrogen or aromatase inhibitor.
Study Details
Timeline
Interventions
20 mg/d
1 mg/d
4 mg q6m
3.6 mg goserelin subcutaneously every 28 days